BPC-157 vs TB-500
The Dose Guy’s verdictOct 27, 20265 sources
For a structural injury, most people run both, and so do I: BPC-157 pinned near the injury every day, TB-500 a couple of times a week anywhere. If you are only buying one, buy BPC-157. It has the deeper track record, a few small human pilots against TB-500’s none, and it covers the gut as well as tendons. BPC-157 alone covers the gut or a small, fresh strain in one spot; TB-500 joins when the injury is big, old, or spread across more than one spot, or when BPC-157 alone has stalled at the four-week check.
How they differ
The difference that matters is reach. BPC-157 works where you put it: people pin it as close to the injury as they can, and take it by mouth for the gut. TB-500 travels. It is a fragment of thymosin beta-4, a repair protein that helps cells migrate into damaged tissue (that is the pitch, not a settled mechanism for the fragment), and people pin it in the belly or shoulder and let it circulate. That is how the community splits the jobs: BPC-157 for the one tendon or the gut, TB-500 for the old shoulder plus the cranky knee plus general wear.
The rhythm is the other thing you will notice. BPC-157 is a small daily habit; TB-500 is a bigger pin twice a week while loading, then once a week. Neither one is a drug you feel the next morning. The change, when it comes, is the movement that hurt last month hurting less, and on TB-500 it sometimes starts with a flare of warmth at old injury sites.
The searches that add a third name are usually two different questions. KPV is a gut anti-inflammatory, worth a look when the gut is inflamed rather than injured, and no help for a tendon. GHK-Cu is the skin peptide; mixed with these two it becomes the GLOW blend, sold for skin quality. For an injury, BPC-157 and TB-500 are the pair with the track record.
What the research shows
One small rat study ran them head to head, and it is the only one published:
Read the rat study for what it is: 32 animals split four ways, the two peptides at different doses, one tendon model. It nudges TB-500 up for tendons. It does not prove the stack works, and the stack’s case rests on years of people running it, not on data.
How people run them
Run BPC-157 at 250–500 mcg a day, sub-q as close to the injury as you can reach, starting at the low end and holding there if it is working. TB-500 loads at 2–2.5 mg twice a week for four to six weeks, pinned anywhere, then drops to once a week or every other week once the problem movement eases. Keep them in separate vials, each reconstituted and refrigerated, so each runs on its own rhythm; a pre-mixed vial locks you into one ratio.
For a structural injury, start both on day one. That is the default stack, and the one I run. If you start on BPC-157 alone, give it four weeks; if healing is still moving, keep going, and if it has stalled, add TB-500 rather than swapping. There is nothing to wash out and no reason to drop BPC-157 when TB-500 arrives. For the gut, BPC-157 runs alone; TB-500 has no gut role.
Two daily-life notes hold for both. Drop the NSAIDs while you run either, because you are trying to rebuild tissue, not quiet it. Keep training the area, light and progressive; controlled loading beats total rest on both. And both are on WADA’s prohibited list, so if you compete in a tested sport, that settles it.
Side effects, side by side
Both are mild on what people report; the real difference is that BPC-157 has a sliver of human safety data and TB-500 has none:
